Evidence map›Paper›PMID 27511838›Full record

ReviewNeuropharmacology2017

The kynurenine pathway and the brain: Challenges, controversies and promises.

Robert Schwarcz, Trevor W Stone

Registry-linked trialOpen access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Neuropharmacology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05986513 (Investigating Brain Abnormalities in People With Knee Osteoarthritis Using MRI), which is not on this map. Cited by 261 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
261citing papers in PubMed, 5 pooled it
7.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05986513 naunknown statusnot on this mapstarted 2023, after this paper: background citation

Investigating Brain Abnormalities in People With Knee Osteoarthritis Using MRI: a Nociplastic Pain Mechanism Based Assessment

TypeinterventionalSponsorToronto Rehabilitation InstituteRan2023 to 2025Enrolled66ConditionsChronic Pain, Central Sensitisation, Knee OsteoarthritisArmsCold Pressor Gel Test
3 · Its place in the literature

Who cites it

261 citing papers in PubMed, 5 syntheses or guidelines pooled it, 433 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. BrainFrontiers in immunology · 2021
    Pooled it
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Review
  12. Article
  13. Review
  14. Review
  15. Review
  16. Article
  17. Review
  18. Review
  19. Article
  20. Review

201 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 2 countries.

Robert SchwarczMaryland Psychiatric Research Center, Department of Psychiatry, University of Maryland School of Medicine, Baltimore, MD, USA. Electronic address: rschwarc@mprc.umaryland.edu.
Trevor W StoneInstitute of Neuroscience and Psychology, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK.
University of Glasgow · GBUniversity of Maryland, Baltimore · US

Funding

The Effects of Kynurenine Aminotransferase Inhibition in People with SchizophreniaP50MH103222 · NIMH · UNIVERSITY OF MARYLAND BALTIMORE · PI SCHWARCZ, ROBERT · 2014 to 2023
$25.2M
NIMH NIH HHS P50 MH103222Wellcome Trust
6 · The paper itself

Abstract

Research on the neurobiology of the kynurenine pathway has suffered years of relative obscurity because tryptophan degradation, and its involvement in both physiology and major brain diseases, was viewed almost exclusively through the lens of the well-established metabolite serotonin. With increasing recognition that kynurenine and its metabolites can affect and even control a variety of classic neurotransmitter systems directly and indirectly, interest is expanding rapidly. Moreover, kynurenine pathway metabolism itself is modulated in conditions such as infection and stress, which are known to induce major changes in well-being and behaviour, so that kynurenines may be instrumental in the etiology of psychiatric and neurological disorders. It is therefore likely that the near future will not only witness the discovery of additional physiological and pathological roles for brain kynurenines, but also ever-increasing interest in drug development based on these roles. In particular, targeting the kynurenine pathway with new specific agents may make it possible to prevent disease by appropriate pharmacological or genetic manipulations. The following overview focuses on areas of kynurenine research which are either controversial, of major potential therapeutic interest, or just beginning to receive the degree of attention which will clarify their relevance to neurobiology and medicine. It also highlights technical issues so that investigators entering the field, and new research initiatives, are not misdirected by inappropriate experimental approaches or incorrect interpretations at this time of skyrocketing interest in the subject matter. This article is part of the Special Issue entitled 'The Kynurenine Pathway in Health and Disease'.

Indexed as

AnimalsBrainHumansKynurenineMetabolic Networks and PathwaysNervous System DiseasesKynurenine3-HydroxykynurenineKynurenic acidNeuroimmunologyNeurologyPsychiatryQuinolinic acid

Identifiers

PMID27511838
PMCPMC5803785
OpenAlexW2508076655

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.